NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V.KvK number 86649051
- Verifiedvalid until 19 Oct 2027
01Overview
About NewAmsterdam Pharma
Short description by MeritVeri
Clinical-stage Dutch biopharmaceutical company developing oral therapies to lower LDL cholesterol, led by the CETP inhibitor obicetrapib, for patients with cardiovascular disease. Its registered office is in Naarden and it also operates through a US subsidiary; revenue comes from a collaboration with Menarini.
On this profile
02Verification
Checked
MeritVeri checks each fact against official public sources, the company's own publications or documentary evidence, and lists exactly what was checked. Nothing on this list can be bought.
Verified on 19 October 2026, valid until the end of 19 October 2027 (Brussels time).
- Official public sourcesBusiness register, central balance sheet office, official gazette, EU VAT system and LEI record
- Published by the companyThe company's own published annual reports and website
- Decided by MeritVeriMeritVeri decides every verification and records it with its date and reference
What was checked
| Item | Checked value | Source | State |
|---|---|---|---|
| Registration number | 86649051 | — | Verified |
| Registered office address | Gooimeer 2 35, 1411DC Naarden | — | Verified |
| Website | https://www.newamsterdampharma.com/ | — | Verified |
| Year founded | 2022 | — | Verified |
| Number of employees | 100 FTEas of 31 Dec 2025 | — | Verified |
| CEO / managing director | 1 personsee People | — | Verified |
| Board of directors | 2 directorssee People | — | Verified |
| Financial statements | FY 2022 – FY 2025 · 4 yearssee Financials | — | Verified |
All items checked on 19 Oct 2026
Outside this verification
- Quality of products and services
- Phone number and email address
- Description, logo and photos
- Social media accounts
- Creditworthiness or future results
Verification cycles
- VRF-NL-2026-000149First verification · Current · 19 Oct 2026 – 19 Oct 2027Verified
03Financials
Four financial years,
Every checked amount was compared with the annual accounts filed with the official register. The result label for each year is always public.
| Metric | FY 20221 Jan – 31 Dec | FY 20231 Jan – 31 Dec | FY 20241 Jan – 31 Dec | FY 20251 Jan – 31 Dec | Trend |
|---|---|---|---|---|---|
| Result | Loss | Loss | Loss | Loss | Profit in 0/4 |
| Revenue | US$102,694,000Verified | US$14,090,000Verified | US$45,563,000Verified | US$22,503,000Verified | -78% since 2022 |
| Net resultafter tax | -US$22,634,000Verified | -US$176,937,000Verified | -US$241,598,000Verified | -US$203,819,000Verified | 2022–2025 |
| Equity | US$430,066,000Verified | US$288,393,000Verified | US$757,500,000Verified | US$683,431,000Verified | +59% since 2022 |
| Gross margin | Not available | Not available | Not available | Not available | — |
| EBITDA | Not available | Not available | Not available | Not available | — |
| Source | — | — | — | — |
FY 20251 Jan – 31 Dec
Loss- Revenue
- US$22,503,000Verified
- Net result
- -US$203,819,000Verified
- Equity
- US$683,431,000Verified
- Gross margin
- Not available
- EBITDA
- Not available
FY 20241 Jan – 31 Dec
Loss- Revenue
- US$45,563,000Verified
- Net result
- -US$241,598,000Verified
- Equity
- US$757,500,000Verified
- Gross margin
- Not available
- EBITDA
- Not available
FY 20231 Jan – 31 Dec
Loss- Revenue
- US$14,090,000Verified
- Net result
- -US$176,937,000Verified
- Equity
- US$288,393,000Verified
- Gross margin
- Not available
- EBITDA
- Not available
FY 20221 Jan – 31 Dec
Loss- Revenue
- US$102,694,000Verified
- Net result
- -US$22,634,000Verified
- Equity
- US$430,066,000Verified
- Gross margin
- Not available
- EBITDA
- Not available
Trend over the years
- Revenue-78% since 2022
- Net result2022–2025
- Equity+59% since 2022
- Gross margin—
- EBITDA—
What the states and labels mean
- Profit · Loss · Break-even
- Based on the net result of the financial year. Break-even: the net result, positive or negative, is at most 1% of that year's revenue. Otherwise a positive net result is a profit and a negative one a loss. If the year has no revenue figure, it is break-even only when the net result is exactly 0.
- Verified
- Checked by MeritVeri against the filed annual accounts or other official sources, in a verification that is valid today.
- Not disclosed
- The company chose not to publish this value.
- Not available
- There is no value for this financial year.
- Amount hidden by the company
- The company chose not to show its amounts. The years, the state of each value and the result of each year stay public.
04People
Who runs and it
Management, owners and board, checked by MeritVeri against official sources such as the official gazette and filed annual accounts, and against the company's own published annual reports.
- Employees
- 100 employees (FTE) · as of 31 Dec 2025
- Verified
CEO / managing director
- Michael DavidsonChief Executive Officer and executive directorSince 2020Verified
Board of directors
- Ian SomaiyaChief Financial OfficerVerified
- BJ JonesChief Commercial OfficerVerified
Only people marked “Verified” were checked by MeritVeri in a valid verification. “Checked earlier” means that verification is no longer valid.
If you are listed here and do not want to be shown, let us know and we will hide your name. More in our privacy policy.
05Business details
Business details
Each detail says where it comes from. Only details marked “Verified” were checked by MeritVeri.
- Legal name
- NewAmsterdam Pharma Company N.V.
- Trading name
- NewAmsterdam Pharma
- KvK number
- 86649051
- Verified
- Registered office
- Gooimeer 2 351411DC NaardenNetherlands
- Verified
- Industry
- Healthcare
- Founded
- 2022
- Verified
- Employees
- 100 FTEas of 31 Dec 2025
- Verified
- Phone
- +31 35 206 2971
Listing updated on 19 Oct 2026 · Report incorrect information
06Awards
Awards
Results of published award editions. Placements are decided by MeritVeri and can never be bought.
No published award results yet.
07Reviews
What people
Experiences of customers, employees and business relations. Every review is checked by MeritVeri before it is published; the company cannot remove or reorder them.
0 published reviews
- 5 stars: 0 of 0
- 4 stars: 0 of 0
- 3 stars: 0 of 0
- 2 stars: 0 of 0
- 1 star: 0 of 0
- Customers
- 0
- Employees
- 0
- Business relations
- 0
No reviews yet
Have you worked with NewAmsterdam Pharma? Share your experience and help others decide.
Only reviews approved by MeritVeri are shown and counted. How reviews work
Is this your company? Claim this profile
Keep the profile up to date, respond to reviews and apply for verification.
Something wrong in this listing?
Tell us and we will check it. Nothing changes without a person looking at it.